Evidence map›Paper›PMID 29203416›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex.

Pharavee Jaiprasart, Bertrand Z Yeung, Ze Lu, M Guillaume Wientjes, Minjian Cui, Chien-Ming Hsieh, Sukyung Woo, Jessie L-S Au

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Pharavee JaiprasartDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States.
Bertrand Z YeungDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States; Optimum Therapeutics LLC, Carlsbad, CA 92008, United States.
Ze LuOptimum Therapeutics LLC, Carlsbad, CA 92008, United States; Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, United States.
M Guillaume WientjesOptimum Therapeutics LLC, Carlsbad, CA 92008, United States; Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, United States.
Minjian CuiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States; Optimum Therapeutics LLC, Carlsbad, CA 92008, United States; Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, United States.
Chien-Ming HsiehCollege of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC.
Sukyung WooDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States.
Jessie L-S AuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States; Optimum Therapeutics LLC, Carlsbad, CA 92008, United States; Institute of Quantitative Systems Pharmacology, Carlsbad, CA 92008, United States; College of Pharmacy, Taipei Medical University, Taipei, Taiwan, ROC. Electronic address: jau@optimumtx.com.
University of Oklahoma Health Sciences Center · USQuantitative BioSciences · USTaipei Medical University · TW

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michael S. Businelle · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HANNAFON, BETHANY · 2012 to 2022
$21.3M
Targeting multiple signaling steps to achieve synergyR01CA163015 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2012 to 2017
$1.9M
Synergistic chemo-siRNA combination therapyR01CA158300 · NCI · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2015
$1.8M
Multiscale computational models for developing combination cancer therapyR01GM100487 · NIGMS · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2014
$1.3M
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designsR01EB015253 · NIBIB · OPTIMUM THERAPEUTICS, LLC · PI AU, JESSIE L.-S., WIENTJES, M GUILLAUME · 2011 to 2014
$1.1M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA158300NCI NIH HHS R01 CA163015NIBIB NIH HHS R01 EB015253NIGMS NIH HHS P20 GM103639NIGMS NIH HHS R01 GM100487
6 · The paper itself

Abstract

RNA Interference (RNAi) is a potentially useful tool to correct the detrimental effects of faulty genes; several RNAi are undergoing clinical evaluation in various diseases. The present study identified the relative contributions of three mechanisms by which polyanion drugs reduced the gene silencing activity of Lipoplex, a complex of small interfering RNA (siRNA) and cationic liposomes. The study used a siRNA against the chemoresistance gene survivin and two model polyanion drugs (suramin, heparin). Products of Lipoplex destabilization were separated, identified, and/or quantified using ultrafiltration, gel electrophoresis, and RT-qPCR (quantitative reverse transcription polymerase chain reaction). Cell binding and endocytosis of fluorescence-labeled Lipoplex and the amount of siRNA at its site of action RISC (RNA-induced silencing complex) were evaluated using endocytosis markers, confocal microscopy, quantitative image analysis, immunoprecipitation, and RT-qPCR. The results show suramin and heparin exerted multiple concentration-dependent effects. First, these agents altered several Lipoplex properties (i.e., reduced particle size, changed surface charge, modified composition of protein biocorona). Second, both caused Lipoplex destabilization to release double- and single-strand siRNA and/or smaller siRNA-lipid complexes with reduced siRNA cargo. Third, both prevented the cell surface binding and internalization of Lipoplex, diminished the siRNA concentration in RISC, and retarded the mRNA knockdown. Suramin and heparin yielded qualitatively and quantitatively different results. Analysis of the experimental results of suramin using quantitative pharmacology (QP) modeling indicated the major cause of gene silencing activity loss depended on drug concentration, changing from inhibition of endocytosis at lower concentration (accounting for 60% loss at ~9μM) to inhibition of cell surface binding and loss of siRNA cargo at higher concentrations (accounting for 64% and 27%, respectively, at 70μM). In summary, the present study demonstrates the complex and dynamic interactions between polyanions and Lipoplex, and the use of QP modeling to delineate the contributions of three mechanisms to the eventual loss of gene silencing activity.

Indexed as

Biological AvailabilityGene SilencingHeparinHT29 CellsHumansLiposomesRNA, Small InterferingSuraminSurvivinTransfectionHeparinLiposomesRNA, Small InterferingSuraminSurvivinAnionic drugBindingBiocoronaDestabilizationInternalizationsiRNA lipoplex

Identifiers

PMID29203416
PMCPMC5808856
OpenAlexW2774557921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.